In the three months ended Sept. 30, 2017 and 2016, we recognized $1.9 million and $1.3 million, respectively, of revenue associated with our Pfizer collaboration.
PHILADELPHIA, Pa., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today financial results for the third quarter of 2017 and recent business progress.
“We have made important progress over the last several months with investigational LUXTURNA™ (voretigene neparvovec) for patients with biallelic RPE65-mediated inherited retinal disease (IRD),” said Jeffrey D. Marrazzo, chief executive officer of Spark Therapeutics. “We are very pleased with the outcome of the Advisory Committee meeting, including the unanimous vote to recommend approval of LUXTURNA, with the completion of FDA pre-approval inspections of our manufacturing facility and clinical trial sites, as well as with our progress preparing for the potential launch of this first pharmacologic treatment for an IRD.”
Additional highlights
Advanced investigational LUXTURNA for the treatment of biallelic RPE65-mediated IRD:
- U.S. Food and Drug Administration’s (FDA) Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended (16-0) approval of LUXTURNA
- Completed FDA pre-approval inspections with no critical observations cited
- Marketing Authorization Application (MAA) has been validated by European Medicines Agency (EMA)
Progressed hemophilia programs:
- Dosed two additional participants in SPK-8011 Phase 1/2 clinical trial - a second participant at 1e12 vg/kg and a first participant at a third dose of 2e12 vg/kg, bringing the number of participants enrolled to five
- SPK-8011 data and SPK-9001 interim data accepted for oral presentations at American Society of Hematology (ASH) annual meeting on Dec. 11, 2017
- Entered into an amendment to the license agreement for SPK-9001 with Pfizer; will receive from Pfizer initial $10 million cash payment and up to an additional $15 million in potential milestone payments upon completion of certain transition activities
Bolstered human capital, technology platform and financial position as we expand our fully integrated organization:
- Entered into a licensing agreement with Genethon for the development and commercialization of an adeno-associated viral (AAV) gene therapy targeting the liver to address a rare genetic disease
- Appointed Federico Mingozzi, Ph.D., as chief scientific officer
- Strong balance sheet with $574.9 million in cash, cash equivalents and marketable securities as of Sept. 30, 2017
Financial results for the quarter ended Sept. 30, 2017
Three Months Ended Sept. 30, 2017 and 2016
In the three months ended Sept. 30, 2017 and 2016, we recognized $1.9 million and $1.3 million, respectively, of revenue associated with our Pfizer collaboration.
Our research and development expenses for the three months ended Sept. 30, 2017 were $39.3 million versus $22.4 million for the three months ended Sept. 30, 2016. The $17.0 million increase was due to a $14.6 million increase in internal research and development expenses, primarily due to increased headcount, and an increase of $2.4 million in external research and development costs. The increase in external research and development was primarily from an increase of $2.3 million in our SPK-FVIII program and $0.1 million in our other clinical programs.
General and administrative expenses for the three months ended Sept. 30, 2017 were $26.6 million versus $12.0 million for the three months ended Sept. 30, 2016. The $14.6 million increase was primarily due to an increase of $7.2 million in salaries and related costs, including stock-based compensation, as a result of increased headcount, an increase of $2.6 million in launch preparation activities for LUXTURNA and $4.8 million in legal and patent expenses, professional fees and other operating costs.
Our net loss for the three months ended Sept. 30, 2017 was $65.0 million, or ($1.90) basic and diluted net loss per common share, as compared with a net loss of $32.6 million, or ($1.07) basic and diluted net loss per common share for the three months ended September 30, 2016.
Nine Months Ended Sept. 30, 2017 and 2016
In the nine months ended Sept. 30, 2017 and 2016, we recognized $4.7 million and $3.9 million, respectively, of revenue associated with our Pfizer collaboration.
Our research and development expenses for the nine months ended Sept. 30, 2017 were $104.7 million versus $60.3 million for the nine months ended Sept. 30, 2016. The $44.4 million increase was due to a $35.4 million increase in internal research and development expenses, primarily due to increased headcount, and an increase of $9.0 million in external research and development. The increase in external research and development was primarily from an increase of $2.9 million in expenses related to LUXTURNA, $2.3 million in our SPK-FVIII program, $2.0 million in our other clinical programs, and $1.8 million in our programs in preclinical development.
During the nine months ended Sept. 30, 2017, we recorded a non-cash impairment charge of $15.7 million related to acquired-in-process research and development from a March 2016 acquisition. Additionally, we recognized an income tax benefit of $1.0 million related to the reversal of the deferred tax liability associated with the IPR&D during the nine months ended Sept. 30, 2017.
General and administrative expenses for the nine months ended Sept. 30, 2017 were $74.8 million versus $31.6 million for the nine months ended Sept. 30, 2016. The $43.2 million increase was primarily due to an increase of $20.7 million in salaries and related costs, including stock-based compensation, as a result of increased headcount, an increase of $7.4 million in launch preparation activities for LUXTURNA and $15.1 million in legal and patent expenses, professional fees and other operating costs.
During the nine months ended September 30, 2017, the Company recorded an income tax benefit of $0.8 million associated with the other comprehensive income.
Our net loss for the nine months ended Sept. 30, 2017 was $191.7 million, or ($5.89) basic and diluted net loss per common share, as compared with a net loss of $86.8 million, or ($3.08) basic and diluted net loss per common share for the nine months ended Sept. 30, 2016.
As of Sept. 30, 2017, we had cash and cash equivalents and marketable securities of $574.9 million, with 36.9 million shares outstanding.
Conference call details
Spark Therapeutics will host a conference call and audio webcast, today, Tuesday, Nov. 7, at 8:30 a.m. ET, to discuss financial results for the third quarter of 2017 and recent business progress. The call can be accessed by dialing the numbers below or by visiting the “Investors” section at www.sparktx.com.
U.S. Dial-in Number: (855) 851-4526
International Dial-in Number: (720) 634-2901
Passcode: 5468349
A replay of the call will be available for one week following the call by dialing the numbers below or also available on our website.
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Passcode: 5468349
About Spark Therapeutics
At Spark Therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. We have successfully applied our technology directed to the retina and liver, and currently have four programs in clinical trials or under regulatory review, including the first potential gene therapy for a genetic disease in the United States and product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease. For more information, visit www.sparktx.com, and follow us on Twitter and LinkedIn.
Cautionary note on forward-looking statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the company’s product candidates, including LUXTURNA (voretigene neparvovec), SPK-7001, SPK-9001 and SPK-8011. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘predict,’’ ‘‘will,’’ ‘‘would,’’ ‘‘could,’’ ‘‘should,’’ ‘‘continue’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that: (i) our BLA or MAA for LUXTURNA may not be approved by the FDA or EMA, respectively; (ii) the data from our Phase 3 clinical trial of LUXTURNA may not support labeling for all biallelic RPE65 mutations other than Leber congenital amaurosis (LCA); (iii) the improvements in functional vision demonstrated by LUXTURNA in our clinical trials may not be sustained over extended periods of time; (iv) interim data from our SPK-7001 Phase 1/2 clinical trial, including data to be generated from our recently expanded cohort, may not support further development of this product candidate; (v) our early preliminary clinical results for our product candidate, SPK-8011, for hemophilia A may not be sustained or sufficient to support further development; (vi) we may be unsuccessful in achieving higher factor VIII activity levels through dose escalation in our phase 1/2 clinical trial of SPK-8011; (vii) our lead SPK-FIX product candidate, SPK-9001, may not produce sufficient data in our Phase 1/2 clinical trial to warrant further development; (viii) our early preliminary data in our phase 1/2 clinical trial of SPK-8011 have yet to be audited and therefore are subject to confirmation in connection with a clinical trial audit; and (ix) any one or more of our product candidates in preclinical or clinical development will not successfully be developed and commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and other filings we make with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Spark Therapeutics undertakes no duty to update this information unless required by law.
Investor Contact:
Ryan Asay
Ryan.asay@sparktx.com
(215) 239-6424
Media Contact:
Monique da Silva
Monique.dasilva@sparktx.com
(215) 282-7470
Spark Therapeutics, Inc.
Consolidated Balance Sheets
(Unaudited)
| December 31, 2016 | September 30, 2017 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 58,923,097 | $ | 146,434,119 | |||
| Marketable securities | 237,242,655 | 332,265,302 | |||||
| Other receivables | 16,780,917 | 6,000,121 | |||||
| Prepaid expenses and other current assets | 1,647,008 | 4,443,407 | |||||
| Total current assets | 314,593,677 | 489,142,949 | |||||
| Marketable securities | 21,900,129 | 96,199,671 | |||||
| Property and equipment, net | 19,794,306 | 25,364,940 | |||||
| Acquired-in-process research and development | 15,490,000 | — | |||||
| Goodwill | 1,160,104 | 1,236,817 | |||||
| Other assets | 924,579 | 723,806 | |||||
| Total assets | $ | 373,862,795 | $ | 612,668,183 | |||
| Liabilities and Stockholders’ Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 9,928,737 | $ | 9,561,865 | |||
| Accrued expenses | 13,826,920 | 15,677,442 | |||||
| Current portion of long-term debt | 302,013 | 309,455 | |||||
| Current portion of deferred rent | 771,196 | 1,043,375 | |||||
| Current portion of deferred revenue | 5,168,674 | 4,377,284 | |||||
| Total current liabilities | 29,997,540 | 30,969,421 | |||||
| Long-term debt | 1,224,003 | 990,973 | |||||
| Long-term deferred rent | 7,498,419 | 10,302,813 | |||||
| Long-term deferred revenue | 3,865,885 | — | |||||
| Deferred tax liability | 1,000,235 | — | |||||
| Total liabilities | 43,586,082 | 42,263,207 | |||||
| Stockholders’ equity: | |||||||
| Preferred stock, $0.001 par value. Authorized, 5,000,000 shares; no shares issued or outstanding | — | — | |||||
| Common stock, $0.001 par value. Authorized, 150,000,000 shares; 30,873,430 shares issued and 30,864,224 shares outstanding as of December 31, 2016; 36,946,198 shares issued and 36,926,603 shares outstanding as of September 30, 2017 | 30,874 | 36,947 | |||||
| Additional paid-in capital | 583,973,682 | 1,015,363,029 | |||||
| Accumulated other comprehensive (loss) income | (794,296 | ) | 232,444 | ||||
| Treasury stock, at cost, 9,206 shares as of December 31, 2016 and 19,595 shares as of September 30, 2017 | (552,636 | ) | (1,185,509 | ) | |||
| Accumulated deficit | (252,380,911 | ) | (444,041,935 | ) | |||
| Total stockholders’ equity | 330,276,713 | 570,404,976 | |||||
| Total liabilities and stockholders’ equity | $ | 373,862,795 | $ | 612,668,183 | |||
Spark Therapeutics, Inc.
Consolidated Statements of Operations
(Unaudited)
| Three months ended September 30, | Nine months ended September 30, | ||||||||||||||
| 2016 | 2017 | 2016 | 2017 | ||||||||||||
| Revenues | $ | 1,302,789 | $ | 1,899,575 | $ | 3,880,046 | $ | 4,657,275 | |||||||
| Operating expenses: | |||||||||||||||
| Research and development | 22,384,109 | 39,341,386 | 60,257,545 | 104,678,902 | |||||||||||
| Acquired in-process research and development | — | 1,750,000 | — | 5,207,142 | |||||||||||
| Impairment of acquired in-process research and development | — | — | — | 15,696,017 | |||||||||||
| General and administrative | 12,049,954 | 26,640,443 | 31,600,567 | 74,782,867 | |||||||||||
| Total operating expenses | 34,434,063 | 67,731,829 | 91,858,112 | 200,364,928 | |||||||||||
| Loss from operations | (33,131,274 | ) | (65,832,254 | ) | (87,978,066 | ) | (195,707,653 | ) | |||||||
| Interest income, net | 568,867 | 1,112,745 | 1,162,833 | 2,230,306 | |||||||||||
| Loss before income taxes | (32,562,407 | ) | (64,719,509 | ) | (86,815,233 | ) | (193,477,347 | ) | |||||||
| Income tax (expense) benefit | — | (292,402 | ) | — | 1,816,323 | ||||||||||
| Net loss | $ | (32,562,407 | ) | $ | (65,011,911 | ) | $ | (86,815,233 | ) | $ | (191,661,024 | ) | |||
| Basic and diluted net loss per common share | $ | (1.07 | ) | $ | (1.90 | ) | $ | (3.08 | ) | $ | (5.89 | ) | |||
| Weighted average basic and diluted common shares outstanding | 30,368,354 | 34,258,328 | 28,218,850 | 32,516,829 | |||||||||||
